WallStSmart

Celestica Inc. (CLS)vsHCA Holdings Inc (HCA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Holdings Inc generates 454% more annual revenue ($76.39B vs $13.79B). HCA leads profitability with a 8.9% profit margin vs 7.0%. CLS appears more attractively valued with a PEG of 1.00. CLS earns a higher WallStSmart Score of 68/100 (B-).

CLS

Strong Buy

68

out of 100

Grade: B-

Growth: 10.0Profit: 7.0Value: 5.7Quality: 5.0
Piotroski: 5/9

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CLS.

HCAFair Value (-4.8%)

Margin of Safety

-4.8%

Fair Value

$506.98

Current Price

$435.19

$71.79 premium

UndervaluedFair: $506.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLS4 strengths · Avg: 9.5/10
Return on EquityProfitability
52.4%10/10

Every $100 of equity generates 52 in profit

Revenue GrowthGrowth
52.8%10/10

Revenue surging 52.8% year-over-year

EPS GrowthGrowth
147.3%10/10

Earnings expanding 147.3% YoY

PEG RatioValuation
1.008/10

Growing faster than its price suggests

HCA4 strengths · Avg: 9.3/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-8.3310/10

Conservative balance sheet, low leverage

Market CapQuality
$95.17B9/10

Large-cap with strong market position

P/E RatioValuation
14.8x8/10

Attractively priced relative to earnings

Areas to Watch

CLS3 concerns · Avg: 2.3/10
Profit MarginProfitability
7.0%3/10

7.0% margin — thin

P/E RatioValuation
46.8x2/10

Premium valuation, high expectations priced in

Price/BookValuation
20.6x2/10

Trading at 20.6x book value

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CLS

The strongest argument for CLS centers on Return on Equity, Revenue Growth, EPS Growth. Revenue growth of 52.8% demonstrates continued momentum. PEG of 1.00 suggests the stock is reasonably priced for its growth.

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : CLS

The primary concerns for CLS are Profit Margin, P/E Ratio, Price/Book. A P/E of 46.8x leaves little room for execution misses.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

CLS profiles as a hypergrowth stock while HCA is a value play — different risk/reward profiles.

CLS carries more volatility with a beta of 1.48 — expect wider price swings.

CLS is growing revenue faster at 52.8% — sustainability is the question.

HCA generates stronger free cash flow (895M), providing more financial flexibility.

Bottom Line

CLS scores higher overall (68/100 vs 63/100) and 52.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Celestica Inc.

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Celestica Inc. provides hardware platforms and supply chain solutions in North America, Europe, and Asia. The company is headquartered in Toronto, Canada.

HCA Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?